Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06412562 D1 Receptor Occupancy Study
NCT02124213Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of razpipadon in Parkinson's disease (PD) and schizophrenia (3 cohorts), sponsored by Pfizer. Primary endpoints: D1 Receptor Occupancy in the striatum at Day 1 and PF-06412562 plasma exposure at Day 1. Started Sep 2014; status: completed.
02
Drugs
razpipadon
03
Conditions
Parkinson's disease (PD)schizophrenia
Beyond the preview
Go deeper on NCT02124213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02124213.